An independent guide to cash-pay care. Every price is dated and sourced.

How we check
Wellchosen Health

Medical weight loss in St. Petersburg

CDC estimates put adult obesity in St. Petersburg at 32.7% and diagnosed diabetes at 12.2% [1]. Florida Medicaid does not pay for GLP-1 drugs for obesity [2], so most St. Pete adults paying for a prescription weight program use cash, an employer plan or, for those on Part D, the Medicare GLP-1 Bridge [3].

Updated Oct 17, 2026By the Wellchosen Health editorial team

Medical review: pending. A licensed clinician has not yet reviewed this page.

Medical weight loss is care from a licensed clinician that uses diet, activity and, when appropriate, FDA-approved anti-obesity medicine, with follow-up for side effects.

Adult obesity, St. Petersburg
32.7% (2023) [1]
Diagnosed diabetes, Pinellas County
13.1% (2023) [4]
Residents 65 and older
21.1% [5]
Florida Medicaid, GLP-1s for obesity
Not covered (Jan 2026) [2]
City population
264,033 (July 2025) [5]

Compare GLP-1 costs

St. Petersburg's health numbers

In CDC PLACES estimates for 2023, 32.7% of St. Petersburg adults have obesity and 12.2% have diagnosed diabetes [1]. Across Pinellas County, the figures are 31.5% and 13.1% [4]. The city has 264,033 residents, and 21.1% are 65 or older [5].

The listing in the box is paid for and labeled. We do not recommend sponsors, and the slot is kept apart from our reporting.

Pills now compete with pens

Two daily GLP-1 pills are approved for weight: the Wegovy pill (oral semaglutide) and Foundayo (orforglipron), approved April 1, 2026 [6] [7]. The Wegovy pill must be taken on an empty stomach with a little water and a 30-minute wait [6]; Foundayo can be taken with or without food [8]. Both start at $149 a month self-pay [9] [10]. Compare in Foundayo vs Wegovy pill and Foundayo.

Self-pay prices, checked Oct 17, 2026
OptionFormMonthly priceSource
FoundayoDaily pill$149 to $299[10]
WegovyDaily pill$149 to $299[9]
WegovyWeekly pen$349[9]
ZepboundWeekly vial or KwikPen$299 to $449[11]
Drug only. The full list is in GLP-1 cost comparison.

Coverage for St. Pete residents

Florida is absent from KFF's January 2026 roster of 13 Medicaid programs that pay for obesity GLP-1s [2]. Medicare is the bigger lever in St. Petersburg, where about one resident in five is 65 or older [5]: Part D members who clear the BMI rules and prior authorization pay a $50 monthly copay for Wegovy, Foundayo or the Zepbound KwikPen until December 31, 2027 [3] [12]. More on insurance and Medicare coverage.

Hospitals in the city

We did not confirm a medical weight loss program or published price at a St. Petersburg hospital, so ask your own hospital system directly.

Questions for any clinic

What to watch for

The labels list pancreatitis, which can show up as belly pain that is severe and will not quit; get it checked [6] [15]. Hives, swelling or trouble breathing need urgent help. Pinellas retirees on insulin or a sulfonylurea should ask how to handle low blood sugar. Because of a boxed warning on thyroid C-cell tumors, skip these drugs with MEN 2 or a personal or family history of medullary thyroid carcinoma. Pregnancy, once recognized, means stopping. Emergencies: 911.

Questions people ask

What is the obesity rate in St. Petersburg, FL?

CDC PLACES estimates 32.7% of St. Petersburg adults had obesity in 2023, compared with 31.5% in Pinellas County [1] [4].

Does Florida Medicaid cover weight loss drugs?

No. Florida Medicaid was not covering GLP-1s for obesity in KFF's January 2026 review of state programs [2].

Is there a GLP-1 pill for weight loss?

Yes. The Wegovy pill and Foundayo are both approved for weight management and start at $149 a month self-pay, checked Oct 17, 2026 [9] [10].

How do St. Petersburg seniors use the Medicare GLP-1 Bridge?

Part D enrollees who meet its rules pay $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, with coverage running through December 31, 2027 [3].

How do I check a weight loss doctor in Florida?

Search the Florida Board of Medicine license lookup at flboardofmedicine.gov [13].

Sources

15 cited
  1. PLACES data, place, 2025 release: St. Petersburg, FL. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
  2. Medicaid coverage of and spending on GLP-1s. KFF, Jan 16, 2026.
  3. Weight loss drugs coverage (Medicare GLP-1 Bridge). Medicare.gov (CMS), accessed 2026-10-17.
  4. PLACES data, county, 2025 release: Pinellas County, FL. Centers for Disease Control and Prevention, 2025 release (2023 BRFSS).
  5. QuickFacts: St. Petersburg city, Florida. U.S. Census Bureau, 2025 estimates and 2020-2024 ACS; accessed 2026-10-17.
  6. Wegovy label (injection and tablets). DailyMed, National Library of Medicine, Jun 2026.
  7. FDA approves Lilly's Foundayo (orforglipron). Eli Lilly and Company, Apr 1, 2026.
  8. Foundayo prescribing information. Eli Lilly and Company, Jul 2026.
  9. Wegovy self-pay offer, NovoCare Pharmacy. Novo Nordisk (NovoCare), Oct 17, 2026.
  10. Foundayo self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
  11. Zepbound self-pay prices on LillyDirect. Eli Lilly and Company (LillyDirect), Oct 17, 2026.
  12. Medicare GLP-1 Bridge: information for pharmacies. Centers for Medicare & Medicaid Services, accessed 2026-10-17.
  13. Florida Board of Medicine. Florida Department of Health, accessed 2026-10-17.
  14. FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, Oct 1, 2026.
  15. Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration, Apr 2026.

This page is general information, not medical advice. Talk with a licensed clinician about your own care.

Compare GLP-1 costs